

May 8, 2025

The Manager- Listing

BSE Limited

Corporate Relationship Dept., 5th Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort,
Mumbai - 400001

The Manager- Listing

National Stock Exchange of India Limited

Exchange plaza, 5th Floor, Plot No. C/1, G Block
Bandra –Kurla Complex, Bandra (E),
Mumbai - 400051

Dear Sir,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015

This is to inform that AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation, Directorate General of Health Services, Government of India to import for sale and distribution of Trastuzumab deruxtecan concentrate for solution for infusion 100 mg [Brand name: ENHERTU®] for an additional indication.

Through this approval, Enhertu is indicated as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2- low (IHC 1+ and IHC 2+/ISH-) or HER2- ultralow (IHC0 with membrane staining) breast cancer, who have received at least one endocrine therapy in metastatic setting.

The receipt of this permission paves way for the marketing of Trastuzumab deruxtecan concentrate for solution for infusion 100 mg [Brand name: ENHERTU®] in India for the specified additional indication, subject to the receipt of related statutory approvals, if any.

We request you to take the above intimation on record.

Thanking you

For **AstraZeneca Pharma India Limited**

Manasa. R
Company Secretary